Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BDTX Stock Summary
Top 10 Correlated ETFs
BDTX
In the News
How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%
The mean of analysts' price targets for Black Diamond Therapeutics (BDTX) points to a 95.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Black Diamond Therapeutics is a precision oncology company targeting genetically defined cancers with its Masterkey approach. Besides NSCLC, BDTX also produced positive early data in recurrent GBM, a notoriously hard-to-treat disease. The company plans to initiate enrollments for expansion cohorts and seek FDA feedback for additional studies on various doses of BDTX-1535.
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. and NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in fireside chats during two upcoming investor conferences:
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced forthcoming presentations during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 11-15, 2023. The three poster presentations include initial dose escalation data from the Company's Phase 1 clinical trial of BDTX-1535 in non-small cell lung cancer (NSCLC), the study design of this ongoing Phase 1 clinical trial, and preclinical data for BDTX-4933.
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. and NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that company management will participate in three upcoming investor conferences:
Why Shares of Black Diamond Therapeutics Skyrocketed This Week
Lung cancer is the deadliest form of cancer in the U.S. Black Diamond Therapeutics' NSCLC therapy is in early trials. The pharmaceutical company used the positive news to raise funds through a stock sale.
Black Diamond Therapeutics stock rockets after positive trial data shows anti-tumor activity
Black Diamond Therapeutics Inc shares doubled after it saw positive initial dose escalation data from a study demonstrating the anti-tumor activity of BDTX-1535 in non-small cell lung (NSCL) cancer patients. The new data from the dose escalation portion of the Phase 1 study demonstrated clinical proof of activity of BDTX-1535 in NSCL cancer patients with both acquired resistance and intrinsic driver epidermal growth factor receptor (EGFR) mutations.
Why Is Black Diamond Therapeutics (BDTX) Stock Up 82%?
Black Diamond Therapeutics (NASDAQ: BDTX ) stock is seeing massive gains on Tuesday after releasing data from the dose escalation portion of the Phase 1 clinical study. That clinical trial covers the use of BDTX-1535 as a treatment for non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM).
Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an overview of the Company's MasterKey programs, including BDTX-1535 and BDTX-4933, at the Jefferies Healthcare Conference on Friday, June 9, 2023, at 12:45 p.m. ET in New York, NY.
Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass. and NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing novel MasterKey therapies targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company's progress at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 12:50 p.m. ET in Boston, MA.
BDTX Financial details
BDTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.26 | -1.99 | -3.4 | -2.33 | -1.88 | |
Operating cash flow per share | -0.76 | -1.58 | -2.77 | -2.35 | -1.52 | |
Free cash flow per share | -0.76 | -1.59 | -2.84 | -2.35 | -1.52 | |
Cash per share | 4.74 | 9.57 | 5.8 | 3.39 | 2.99 | |
Book value per share | -1.56 | -3.59 | -6.74 | -9.25 | 2.66 | |
Tangible book value per share | -1.56 | 9.35 | -6.74 | 3.19 | 2.66 | |
Share holders equity per share | -1.56 | -3.59 | -6.74 | -9.25 | 2.66 | |
Interest debt per share | 6.15 | 0.27 | 0.79 | 0.67 | 0.58 | |
Market cap | 1.29B | 1.05B | 192.89M | 65.21M | 123.51M | |
Enterprise value | 1.33B | 1.03B | 155.55M | 59.04M | 92.59M | |
P/E ratio | -31.32 | -16.11 | -1.57 | -0.77 | -1.5 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -52.22 | -20.23 | -1.93 | -0.77 | -1.85 | |
PFCF ratio | -52.18 | -20.17 | -1.88 | -0.76 | -1.85 | |
P/B Ratio | -25.28 | -8.92 | -0.79 | -0.19 | 1.06 | |
PTB ratio | -25.28 | -8.92 | -0.79 | -0.19 | 1.06 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -58.17 | -15.3 | -1.24 | -0.62 | -1.08 | |
EV to operating cash flow | -54.08 | -19.73 | -1.55 | -0.69 | -1.39 | |
EV to free cash flow | -54.03 | -19.68 | -1.51 | -0.69 | -1.39 | |
Earnings yield | -0.03 | -0.06 | -0.64 | -1.3 | -0.67 | |
Free cash flow yield | -0.02 | -0.05 | -0.53 | -1.31 | -0.54 | |
Debt to equity | -3.94 | -0.07 | -0.12 | -0.08 | 0.22 | |
Debt to assets | 1.27 | 0.03 | 0.11 | 0.18 | 0.16 | |
Net debt to EBITDA | -2 | 0.38 | 0.3 | 0.06 | 0.36 | |
Current ratio | 31.8 | 22.48 | 8.87 | 8.37 | 6.82 | |
Interest coverage | 0 | -69.57K | 0 | 23.75 | 0 | |
Income quality | 0.7 | 0.78 | 0.8 | 0.93 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.03 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.45 | -2.73 | -13.22 | -0.38 | -0.08 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 6.66 | 12.68 | 22.72 | 22.03 | 10.59 | |
ROIC | -0.07 | 0.67 | 0.67 | 0.32 | -0.53 | |
Return on tangible assets | -0.26 | -0.2 | -0.5 | -0.54 | -0.52 | |
Graham Net | -1.67 | 8.91 | -7.78 | 2.27 | 2.04 | |
Working capital | 149.8M | 305.34M | 186.14M | 112.45M | 114.39M | |
Tangible asset value | -50.97M | 307.76M | -243.82M | 115.7M | 116.74M | |
Net current asset value | -54.6M | 297.64M | -281.72M | 87.15M | 92.2M | |
Invested capital | -3.94 | -0.07 | -0.12 | -0.08 | 0.22 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.19M | 2.25M | 3.32M | 2.99M | 2.1M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 15.25K | 1.54K | 676.16 | 211.58 | 1.94K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.02 | 0.24 | 0.54 | 1.73 | 0.19 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.81 | 0.55 | 0.51 | 0.25 | -0.71 | |
Capex per share | 0 | 0 | -0.07 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.47 | -0.55 | -0.52 | -0.45 | -0.38 | |
Operating cash flow per share | -0.6 | -0.55 | -0.39 | -0.36 | -0.27 | |
Free cash flow per share | -0.6 | -0.55 | -0.39 | -0.36 | -0.27 | |
Cash per share | 3.37 | 2.83 | 2.45 | 2.83 | 2.54 | |
Book value per share | -9.21 | -9.75 | 2.25 | 2.64 | 2.26 | |
Tangible book value per share | 3.18 | 2.69 | 2.25 | 2.64 | 2.26 | |
Share holders equity per share | -9.21 | -9.75 | 2.25 | 2.64 | 2.26 | |
Interest debt per share | 0.74 | 0.73 | 0.73 | 0.51 | 0.49 | |
Market cap | 65.5M | 68.95M | 184.41M | 146.21M | 145.1M | |
Enterprise value | 59.33M | 57.27M | 169.28M | 114.27M | 114.18M | |
P/E ratio | -0.96 | -0.85 | -2.41 | -1.59 | -1.87 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -2.99 | -3.44 | -12.83 | -7.96 | -10.4 | |
PFCF ratio | -3.01 | -3.44 | -12.83 | -7.95 | -10.4 | |
P/B Ratio | -0.2 | -0.19 | 2.24 | 1.09 | 1.24 | |
PTB ratio | -0.2 | -0.19 | 2.24 | 1.09 | 1.24 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.46 | -2.66 | -8.5 | -4.76 | -5.5 | |
EV to operating cash flow | -2.7 | -2.86 | -11.78 | -6.22 | -8.18 | |
EV to free cash flow | -2.73 | -2.86 | -11.78 | -6.21 | -8.18 | |
Earnings yield | -0.26 | -0.29 | -0.1 | -0.16 | -0.13 | |
Free cash flow yield | -0.33 | -0.29 | -0.08 | -0.13 | -0.1 | |
Debt to equity | -0.08 | -0.08 | 0.33 | 0.19 | 0.22 | |
Debt to assets | 0.18 | 0.2 | 0.22 | 0.15 | 0.16 | |
Net debt to EBITDA | 0.26 | 0.54 | 0.76 | 1.33 | 1.49 | |
Current ratio | 8.37 | 8.4 | 6.69 | 9.76 | 6.82 | |
Interest coverage | 16.14 | 31.43 | 0 | 0 | 0 | |
Income quality | 1.04 | 0.96 | 0.75 | 0.8 | 0.72 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.01 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 1.59 | 0 | 0 | -0.29 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 9.85 | 11.02 | 5.15 | 5.18 | 4.37 | |
ROIC | 0.07 | 0.07 | -0.14 | -0.13 | -0.13 | |
Return on tangible assets | -0.11 | -0.15 | -0.16 | -0.13 | -0.12 | |
Graham Net | 2.26 | 1.81 | 1.42 | 2.08 | 1.73 | |
Working capital | 112.45M | 95.13M | 79.09M | 131.98M | 114.39M | |
Tangible asset value | 115.7M | 98.19M | 82.2M | 134.32M | 116.74M | |
Net current asset value | 87.15M | 70.59M | 55.31M | 108.98M | 92.2M | |
Invested capital | -0.08 | -0.08 | 0.33 | 0.19 | 0.22 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 3.82M | 2.46M | 2.89M | 1.72M | 1.51M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 209.33 | 337.61 | 303.36 | 75.89 | 2.43K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.43 | 0.27 | 0.3 | 1.19 | 0.04 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.05 | 0.06 | -0.23 | -0.17 | -0.17 | |
Capex per share | 0.01 | 0 | 0 | 0 | 0 |
BDTX Frequently Asked Questions
What is Black Diamond Therapeutics, Inc. stock symbol ?
Black Diamond Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol BDTX
What is Black Diamond Therapeutics, Inc. stock quote today ?
Black Diamond Therapeutics, Inc. stock price is $4.9 today.
Is Black Diamond Therapeutics, Inc. stock public?
Yes, Black Diamond Therapeutics, Inc. is a publicly traded company.